ImmunoGen IMGN today announced that Novartis NVS has licensed the exclusive
right to use the Company's ADC technology to develop anticancer
therapeutics to an undisclosed target.
“We believe the therapies Novartis is developing with our ADC technology
have the potential to make an important difference for patients,”
commented Daniel Junius, President and CEO.
This is the second license to be taken by Novartis under a 2010
agreement between the companies. For each license, ImmunoGen receives an
upfront payment and is entitled to receive milestone payments
potentially totaling approximately $200 million plus royalties on
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in